Suppr超能文献

MAPK 抑制增强放射性碘难治性甲状腺癌摄取放射性碘(ERRITI):一项单中心前瞻性双臂研究。

Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.

机构信息

Clinic for Nuclear Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

German Cancer Consortium (DKTK) partner site Essen, Essen, Germany.

出版信息

Clin Cancer Res. 2022 Oct 3;28(19):4194-4202. doi: 10.1158/1078-0432.CCR-22-0437.

Abstract

PURPOSE

Restoration of iodine incorporation (redifferentiation) by MAPK inhibition was achieved in previously radioiodine-refractory, unresectable thyroid carcinoma (RR-TC). However, results were unsatisfactory in BRAFV600E-mutant (BRAF-MUT) RR-TC. Here we assess safety and efficacy of redifferentiation therapy through genotype-guided MAPK-modulation in patients with BRAF-MUT or wildtype (BRAF-WT) RR-TC.

PATIENTS AND METHODS

In this prospective single-center, two-arm phase II study, patients received trametinib (BRAF-WT) or trametinib + dabrafenib (BRAF-MUT) for 21 ± 3 days. Redifferentiation was assessed by 123I-scintigraphy. In case of restored radioiodine uptake, 124I-guided 131I therapy was performed. Primary endpoint was the redifferentiation rate. Secondary endpoints were treatment response (thyroglobulin, RECIST 1.1) and safety. Parameters predicting successful redifferentiation were assessed using a receiver operating characteristic analysis and Youden J statistic.

RESULTS

Redifferentiation was achieved in 7 of 20 (35%) patients, 2 of 6 (33%) in the BRAF-MUT and 5 of 14 (36%) in the BRAF-WT arm. Patients received a mean (range) activity of 300.0 (273.0-421.6) mCi for 131I therapy. Any thyroglobulin decline was seen in 57% (4/7) of the patients, RECIST 1.1 stable/partial response/progressive disease in 71% (5/7)/14% (1/7)/14% (1/7). Peak standardized uptake value (SUVpeak) < 10 on 2[18F]fluoro-2-deoxy-D-glucose (FDG)-PET was associated with successful redifferentiation (P = 0.01). Transient pyrexia (grade 3) and rash (grade 4) were noted in one patient each.

CONCLUSIONS

Genotype-guided MAPK inhibition was safe and resulted in successful redifferentiation in about one third of patients in each arm. Subsequent 131I therapy led to a thyroglobulin (Tg) decline in more than half of the treated patients. Low tumor glycolytic rate as assessed by FDG-PET is predictive of redifferentiation success. See related commentary by Cabanillas et al., p. 4164.

摘要

目的

通过 MAPK 抑制恢复碘摄取(再分化)已在先前放射性碘难治性、不可切除的甲状腺癌(RR-TC)中实现。然而,在 BRAFV600E 突变(BRAF-MUT)RR-TC 中结果并不令人满意。在此,我们通过基因型指导的 MAPK 调节评估 BRAF-MUT 或野生型(BRAF-WT)RR-TC 患者的再分化治疗的安全性和疗效。

患者和方法

在这项前瞻性、单中心、两臂的 II 期研究中,患者接受了 21 ± 3 天的曲美替尼(BRAF-WT)或曲美替尼+达拉非尼(BRAF-MUT)治疗。通过 123I 闪烁扫描评估再分化情况。在恢复放射性碘摄取的情况下,进行 124I 引导的 131I 治疗。主要终点是再分化率。次要终点是治疗反应(甲状腺球蛋白、RECIST 1.1)和安全性。使用接收者操作特征分析和 Youden J 统计评估预测成功再分化的参数。

结果

在 20 名患者中,有 7 名(35%)实现了再分化,其中 2 名(33%)在 BRAF-MUT 组,5 名(36%)在 BRAF-WT 组。患者接受的 131I 治疗平均(范围)活度为 300.0(273.0-421.6)mCi。7 名患者中的 5 名(57%)出现任何甲状腺球蛋白下降,71%(5/7)为 RECIST 1.1 稳定/部分缓解/进展,14%(1/7)为疾病进展。2[18F]氟-2-脱氧-D-葡萄糖(FDG)-PET 上的最大标准化摄取值(SUVpeak)<10 与成功再分化相关(P = 0.01)。1 名患者出现短暂发热(3 级),1 名患者出现皮疹(4 级)。

结论

基因型指导的 MAPK 抑制是安全的,在每个臂的大约三分之一的患者中导致成功再分化。随后的 131I 治疗导致超过一半的治疗患者甲状腺球蛋白(Tg)下降。通过 FDG-PET 评估的肿瘤糖酵解率低是再分化成功的预测因素。请参阅相关评论文章,由 Cabanillas 等人撰写,第 4164 页。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6db7/9527501/802ab004f52b/4194fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验